EYENのチャート
EYENの企業情報
| symbol | EYEN |
|---|---|
| 会社名 | Eyenovia Inc （アイノビア） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- アイノビアは米国のバイオ医薬品メ―カ―。主に眼科用医薬品の開発・商業化に注力する。同社の主な候補薬には、慢性閉塞隅角緑内障の治療薬「MicroProst」、散瞳の治療を対象とする「MicroStat」、ドライアイ治療薬の「MicroTears」、近視治療薬「MicroPine」などがある。本社所在地はニューヨーク。 Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. |
| 本社所在地 | 501 Fifth Avenue Suite 1404 New York NY 10017 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 41699 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.eyenoviabio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/eyen |
| adr_tso | ― |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 3.97 |
| 時価総額（marketcap） | 39694624.62 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
EYENのテクニカル分析
EYENのニュース
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2021 Results - Earnings Call Transcript 2022/03/29 02:13:03 Seeking Alpha
Eyenovia GAAP EPS of $0.10 beats by $0.32, revenue of $10M 2022/03/28 20:13:09 Seeking Alpha
Eyenovia press release (EYEN): Q4 GAAP EPS of $0.10 beats by $0.32.Revenue of $10M (+400.0% Y/Y).As of December 31, 2021, the Company’s cash and cash equivalents were approximately…
Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results 2022/03/28 20:05:00 GlobeNewswire
Successfully completed Type A meeting with FDA and anticipates MydCombi™ NDA resubmission in Q3 2022
Eyenovia Raises 15M Via Equity To Advance MydCombi Program 2022/03/04 14:07:56 Benzinga
Eyenovia Inc (NASDAQ: EYEN ) has entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd for gross proceeds of $15 million . The offering includes 3 million shares, pre-funded warrants to purchase up to 1.87 million shares, and common warrants to purchase up to 4.87 million shares. The aggregate offering price for each share of … Full story available on Benzinga.com
Eyenovia receives $15M institutional capital investment from Armistice Capital 2022/03/04 12:44:29 Seeking Alpha
Eyenovia (EYEN) trades 2.3% down premarket after it entered into a securities purchase agreement with Armistice Capital Master Fund in an offering of 3M shares of its common…
Eyenovia: Recent MicroLine Data, October MydCombi PDUFA Date Bode Well For Value Creation 2021/06/02 10:10:14 Seeking Alpha
Chasing Allergan, Eyenovia hits endpoint in vision phase 3 2021/05/28 07:46:30 FiercePharma
Chasing Allergan, Eyenovia hits endpoint in vision phase 3 ntaylor Fri, 05/28/2021 - 03:46
Eyenovia (EYEN) Gets a Buy Rating from Northland Securities 2021/05/26 14:00:17 Smarter Analyst
Northland Securities analyst Tim Chiang maintained a Buy rating on Eyenovia (EYEN) yesterday and set a price target of $12.00. The post Eyenovia (EYEN) Gets a Buy Rating from Northland Securities appeared first on Smarter Analyst .
Eyenovia Stock Shoots Higher on Positive MicroLine Data in Late-Stage Presbyopia Study 2021/05/25 15:18:54 Benzinga
Eyenovia Inc (NASDAQ: EYEN ) has announced topline data from its VISION-1 Phase 3 study evaluating MicroLine, for the temporary improvement of near vision in adults with presbyopia. The results will be presented at a future ophthalmic-focused medical meeting. The study met its primary endpoint with a statistically significant proportion of subjects treated with MicroLine showing Full story available on Benzinga.com
Stock Alert: Eyenovia Up 10% On Positive Late-stage Study Results Of Its MicroLine 2021/05/25 14:12:32 RTT News
Shares of Eyenovia, Inc. (EYEN) are rising more than 10% Tuesday morning after the company announced positive top line results from the late-stage study of MicroLine for the treatment of Presbyopia.